1. Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity;Stoller;N. Engl. J. Med.,1977
2. Early clinical studies with cis-diammine-1,1-cyclobutanedicarboxylate platinum II;Calvert;Cancer Chemother. Pharmacol.,1982
3. Phase I clinical and pharmacologic trial of carboplatin daily for 5 days;Van Echo;Cancer Treat. Rep.,1984
4. Pharmacokinetics and dosage reduction of cis-diammine(1,1-cyclobutanedicarboxylato)platinum in patients with impaired renal function;Egorin;Cancer Res.,1984
5. The pharmacokinetics of cis-diammine-1,1-cyclobutane dicarboxylate platinum (II) (CBDCA) in patients with normal and impaired renal function;Harland;Cancer Res.,1984